Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
Date:8/8/2011

THE WOODLANDS, Texas, Aug. 8, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.  

Progress in Clinical Pipeline

  • Lexicon commenced a Phase 2b clinical trial for LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2.  The company also presented data at the 71st Scientific Sessions of the American Diabetes Association from a mechanistic study designed to investigate the effect of LX4211 on peptide hormones in the intestinal tract in patients with type 2 diabetes.  The data from the study demonstrated that a single dose of LX4211 significantly increased GLP-1 (total and active) and PYY, important mediators of glycemic and appetite control.  
  • Lexicon successfully completed a Phase 1 study of LX1033, a serotonin synthesis inhibitor being developed as a potential treatment for irritable bowel syndrome (IBS).  Results from the study demonstrated that LX1033 was well tolerated at all doses and produced a statistically significant reduction in serotonin synthesis compared to placebo, as measured by both plasma (p<0.001) and urinary (p<0.01) 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for serotonin synthesis.  Importantly, a greater reduction in serotonin synthesis was achieved with lower and less frequent dosing than was observed with Lexicon's first generation serotonin synthesis inhibitor, LX1031, which had previously demonstrated improvements in global assessment of adequate relief and
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
    2. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
    3. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
    4. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
    5. Lexicon to Provide First Quarter 2011 Financial Results
    6. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
    7. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    9. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    10. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    11. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... 30, 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... that the company,s Bridgewater, New Jersey ... Food and Drug Administration (FDA) relating to an inspection ... to Sculptra Aesthetic injectable, which was divested to Galderma ... management of Valeant,s contract manufacturers (rather than Valeant,s own ...
    (Date:9/30/2014)... 30, 2014 The Eastern European medical device ... providers as well as new medical-device manufacturers are constantly ... looking at ways to reduce the cost incurred for ... one of the effective means to achieve this target. ... in Eastern European and provides profiles of key distributors ...
    (Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
    Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
    ... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
    ... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
    Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
    (Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
    (Date:9/30/2014)... for doctors to measure damaging "brain tsunamis" in ... a step closer to reality, thanks to pioneering ... Institute. , The research team, led by Jed ... of neurosurgery at the UC College of Medicine, ... through an injured brain like tsunami wavescan be ...
    (Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
    (Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new ... at higher rates than other primary care practices ... according to results of a new 10-state University ... Medical Care . , Using data from a ... 2013, the investigators found that FQHCs community ...
    (Date:9/30/2014)... EverStryke , the permanent match currently offered by ... a free book and class all about survival education and ... investigative review. , “Joe Marshall of SurvivalLife.com is one ... niche, and this product is an excellent way to get ... that Joe offers on his website to help people be ...
    Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2
    ... research published in the December issue of the ... that the American College of Surgeons National Surgical Quality ... assessing outcomes of uncommon, high-risk surgical procedures, including pancreatic ... on this particular procedure has been available and analyzed, ...
    ... finding a cure for amyotrophic lateral sclerosis (ALS, or ... to help more researchers identify treatment candidates that increase ... The Jackson Laboratory will provide the most widely used ... work with them, to researchers participating in the Prize4Life ...
    ... ... getting recommended eye exam; EyeSmart: EyeCommitted social media campaign seeks to reduce the largest ... ... more new cases of legal blindness among working-age Americans than any other disease. If ...
    ... , ST. LOUIS, Dec. 10 Centene Corporation (NYSE: ... release its 2010 financial guidance at approximately 6:00 AM (Eastern ... call afterwards at approximately 8:30 AM (Eastern Time) to discuss ... Chief Executive Officer, and William N. Scheffel, Executive Vice President, ...
    ... , CINCINNATI, Dec. 10 Streamline Health Solutions, ... document workflow solutions for hospitals, today announced that St. ... Health to provide a workflow solution to ensure compliance ... (VPP) promotes effective worksite-based safety and health. St. Vincent,s ...
    ... ... Home Care as well as one system encompassing virtually every clinical, operational and financial aspect ... , ... 10, 2009 -- Fastrack Healthcare Systems announced today the completion of the first phase ...
    Cached Medicine News:Health News:Surgical quality program is a strong tool for assessing outcomes for high-risk procedures 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 3Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 2Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 3Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 2Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 4Health News:Fastrack Announces Major Expansion 2Health News:Fastrack Announces Major Expansion 3
    The extended lip of the lower jaw assists in placing the lower jaw underneath less-mobile menisci....
    The Smith & Nephew ACUFEX DUCKLING punches are a lower-profile relation to the Duckbill, maintaining a large square bite and maximizing maneuverability....
    For the specific requirements of the posterior horn of the meniscus; the short, low profile jaw facilitates working in the tight confines of the posterior aspect of the knee....
    The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
    Medicine Products: